Preview

Russian Journal of Cardiology

Advanced search

Chronic kidney disease: definition, classification, diagnostics, and treatment

https://doi.org/10.15829/1560-4071-2013-4-95-103

Abstract

Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). At the same time, CKD is an independent risk factor of CVD and mortality. CVD and CKD share common conventional risk factors (such as arterial hypertension, diabetes mellitus, obesity, and dyslipidemia). The combination of CVD and CKD is associated with such non-conventional renal risk factors as hyperhydratation, anemia, phosphorus and calcium metabolism disturbances,systemic inflammation,  and hypercoagulation, which can also influence the development and pathogenesis of CVD. 

High prevalence of renal dysfunction and adverse prognostic role of reduced glomerular filtration rate (GFR) and albuminuria justified the development of the universal therapeutic strategy for CKD patients. The latest version of these recommendations was published in 2013, as a part of the KDIGO (Kidney Disease Improving Global Outcomes) initiative. The latest KDIGO recommendations classify CKD not only by GFR categories, but also by albuminuria levels, which provides an opportunity to stratify patients by their complication risk. The new classification is based on the evidence demonstrating that the risks of total and cardiovascular mortality, acute renal damage, and CKD progression substantially differ by the levels of urinary albumin excretion, regardless of GFR values. 

The need for early diagnostics of renal and cardiovascular dysfunction, in order to stratify risk levels and define the therapeutic strategy and tactics, is also reflected by the updates of the national and international recommendations on arterial hypertension, atherosclerosis, and cardiovascular prevention.

About the Authors

Zh. D. Kobalava
Russian University of People’s Friendship, Moscow, Russia
Russian Federation


S. V. Villevalde
Russian University of People’s Friendship, Moscow, Russia
Russian Federation


M. A. Efremovtseva
Russian University of People’s Friendship, Moscow, Russia
Russian Federation


References

1. Go A. S., Chertow G. M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296–305.

2. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III) J Am SocNephrol 2002; 13 (5):1338–49.

3. Anavekar N. S., McMurray J. J., Velazquez E. J. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285–95.

4. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 1): SI-266.

5. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Supplement 2013; 3:1–150.

6. 2013 ESH/ESC Guidelines for the management of arterial hypertension Eur Heart J – doi:10.1093/eurheartj/eht151.

7. ESC/EAS Guidelines for the management of dyslipidaemias. EurHeartJ 2011; 32:1769–818.

8. Diagnostics and correction of impairedlipidmetabolismfor the prevention and treatment of atherosclerosis. Russian guidelines. V revision. Moscow, 2012. http://cardioline.ru/uploads/Full%20Guidelines.pdf. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Москва, 2012 г. http://cardioline.ru/uploads/Full%20Guidelines.pdf).

9. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 2012; 33,1635–701.

10. Functional condition of kidneys and forecasting of cardiovasculare risk. Guidelines of VNOK and NONR. Cardiovascular Therapy and Prevention.. 2008; 7 (6). Supplement 3. Russian. (Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации ВНОК и НОНР. Кардиоваскулярная терапия и профилактика. 2008; 7 (6). Приложение 3).

11. National guidelines. Chronic kidney disease: basic positions, definition, diagnostics, screening, approaches to prevention and treatment. Project. http://j.nephrol.ru/ckd/09.10.2011. Russian (Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению. Проект. http://j.nephrol.ru/ckd/ 09.10.2011).

12. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375 (9731):2073–81.

13. Chronic Kidney Disease Prognosis Consortium, van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79 (12):1341–52.

14. Levey A. S., de Jong P. E., Coresh J. et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.Kidney Int 2011; 80 (1):17–28.

15. Levey A. S., Stevens L. A., Schmid C. H. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–12.

16. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28,1462–536.

17. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int (Suppl.) 2012; 2 (5):1–85.

18. Lewis J. B. Blood pressure control in chronic kidney disease: is less really more? J Am SocNephrol 2010; 21:1086–92.

19. Klahr S., Levey A. S., Beck G. J. et al. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. Modi

20. Wright J. T. Jr., Bakris G., Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421–31.

21. Ruggenenti P., Perna A., Loriga G. et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005; 365:939–46.

22. Sarnak M. J., Greene T., Wang X. et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modi

23. Appel L. J., Wright J. T. Jr., Greene T. et al. Intensive blood-pressure control in hypertensive chronic kidney disease.NEngl J Med 2010; 363:918–29.

24. Arguedas J. A., Perez M. I., Wright J. M. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009: CD004349.

25. Upadhyay A., Earley A., Haynes S. M., et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modi er. Ann Intern Med 2011; 154:541–8.

26. Kunz R., Friedrich C., Wolbers M., et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30–48.

27. Haller H., Ito S., Izzo J. L. Jr. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.NEngl J Med 2011; 364:907–17.

28. Ruggenenti P., Fassi A., Ilieva A. P. et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens 2011; 29:207–16.

29. Wald D. S., Law M., Morris J. K. et al. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290–300.

30. Bakris G. L., Sera

31. Parving H. H., Brenner B. M., McMurray J.J.V. et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204–13.

32. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–59.

33. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–78.

34. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010; 376:1670–81.

35. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377 (9784):2181–92.

36. Instruction for medical use of the drug Inegy. http://www.rlsnet.ru/tn_index_id_41541.htmRussian (Инструкция по медицинскому применению лекарственного препарата ИНЕДЖИ. http://www.rlsnet.ru/tn_index_id_41541.htm).

37. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J KidneyDis. 2012; 60 (5):850–86.


Review

For citations:


Kobalava Zh.D., Villevalde S.V., Efremovtseva M.A. Chronic kidney disease: definition, classification, diagnostics, and treatment. Russian Journal of Cardiology. 2013;(4):95-103. (In Russ.) https://doi.org/10.15829/1560-4071-2013-4-95-103

Views: 1827


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)